Vontobel Swiss Wealth Advisors AG bought a new position in CVS Health Corp (NYSE:CVS) in the third quarter, HoldingsChannel reports. The fund bought 25,703 shares of the pharmacy operator’s stock, valued at approximately $2,090,000. CVS Health makes up approximately 1.3% of Vontobel Swiss Wealth Advisors AG’s holdings, making the stock its 23rd biggest holding.

Other institutional investors and hedge funds also recently modified their holdings of the company. Perkins Coie Trust Co increased its holdings in CVS Health by 7.9% during the 2nd quarter. Perkins Coie Trust Co now owns 26,741 shares of the pharmacy operator’s stock valued at $2,152,000 after purchasing an additional 1,948 shares in the last quarter. City Holding Co. increased its holdings in CVS Health by 11.9% during the 2nd quarter. City Holding Co. now owns 23,411 shares of the pharmacy operator’s stock valued at $1,884,000 after purchasing an additional 2,482 shares in the last quarter. Atria Investments LLC increased its holdings in CVS Health by 14.8% during the 2nd quarter. Atria Investments LLC now owns 33,935 shares of the pharmacy operator’s stock valued at $2,730,000 after purchasing an additional 4,372 shares in the last quarter. Gillespie Robinson & Grimm Inc. increased its holdings in CVS Health by 3.2% during the 2nd quarter. Gillespie Robinson & Grimm Inc. now owns 296,923 shares of the pharmacy operator’s stock valued at $23,890,000 after purchasing an additional 9,327 shares in the last quarter. Finally, Capital Investment Advisors LLC increased its holdings in CVS Health by 8.2% during the 2nd quarter. Capital Investment Advisors LLC now owns 13,479 shares of the pharmacy operator’s stock valued at $1,085,000 after purchasing an additional 1,023 shares in the last quarter. 81.69% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.61% of the stock is owned by company insiders.

CVS Health Corp (NYSE:CVS) opened at $79.44 on Wednesday. CVS Health Corp has a 12-month low of $66.45 and a 12-month high of $84.72. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55. The stock has a market capitalization of $80,470.00, a price-to-earnings ratio of 16.41, a PEG ratio of 1.25 and a beta of 0.90.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The business had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. During the same period last year, the company earned $1.64 EPS. The firm’s revenue was up 3.5% on a year-over-year basis. research analysts anticipate that CVS Health Corp will post 5.89 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th will be given a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.52%. CVS Health’s dividend payout ratio is currently 41.32%.

CVS has been the subject of a number of recent analyst reports. Leerink Swann reaffirmed an “outperform” rating and set a $85.00 price target (down from $90.00) on shares of CVS Health in a report on Tuesday, November 7th. Oppenheimer reaffirmed a “buy” rating and set a $95.00 price target on shares of CVS Health in a report on Monday, October 9th. Raymond James Financial raised CVS Health from an “outperform” rating to a “strong-buy” rating and set a $90.00 target price for the company in a research note on Thursday, January 4th. They noted that the move was a valuation call. SunTrust Banks set a $85.00 target price on CVS Health and gave the company a “buy” rating in a research note on Thursday, October 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of CVS Health in a research note on Thursday, October 12th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $86.63.

COPYRIGHT VIOLATION NOTICE: This story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://theolympiareport.com/2018/01/17/vontobel-swiss-wealth-advisors-ag-buys-shares-of-25703-cvs-health-corp-cvs.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.